RecruitingPhase 1Phase 2NCT05421663

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

A Phase 1b/2, Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants With B-cell Non-Hodgkin Lymphoma

Sponsor

Janssen Research & Development, LLC

Enrollment

439 participants

Start Date

Aug 12, 2022

Study Type

INTERVENTIONAL

Conditions

Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse

Summary

This is a Phase 1b/2, multicenter, open-label, study of prizloncabtagene autoleucel (prizlo-cel), an autologous dual targeting chimeric antigen receptor (CAR) T-cell therapy targeting both cluster of differentiation (CD) CD20 and CD19, for the treatment of adult participants with relapsed or refractory (r/r) B-Cell non-Hodgkin lymphoma (B-NHL) or frontline high-risk diffuse large B-cell lymphoma (DLBCL).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new bispecific antibody called JNJ-90014496 that targets two proteins on the surface of B-cell lymphoma cells. By latching onto both targets simultaneously, this drug may be more effective at killing lymphoma cells while having an acceptable safety profile. **You may be eligible if...** - You are 18 or older - You have a confirmed B-cell non-Hodgkin lymphoma (blood/immune system cancer) - Your tumor is confirmed to express CD19 and/or CD20 markers on lab testing - You have relapsed (cancer came back) or refractory (cancer did not respond) disease after prior treatment - Your overall health is adequate to participate in a clinical trial **You may NOT be eligible if...** - You have central nervous system involvement of your lymphoma - You have had certain prior targeted therapies that overlap with this study - You have active autoimmune disease or significant infections - You are pregnant or breastfeeding - You have significant heart, liver, or kidney problems Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALPrizloncabtagene autoleucel (Prizlo-Cel)

Prizlo-Cel, an autologous dual targeting chimeric antigen receptor (CAR) - T cell therapy targeting Cluster of differentiation (CD)20 and CD19.

Locations(32)

City of Hope

Duarte, California, United States

Colorado Blood Cancer Institute

Denver, Colorado, United States

University of Iowa Hospital and Clinics

Iowa City, Iowa, United States

University of Kentucky Medical Center

Lexington, Kentucky, United States

Rutgers Cancer Institute of New Jersey

Piscataway, New Jersey, United States

Levine Cancer Institute

Charlotte, North Carolina, United States

University Hospitals Cleveland Medical Center

Cleveland, Ohio, United States

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Greco Hainesworth Tennessee Oncology Centers for Research

Nashville, Tennessee, United States

Sarah Cannon Research Institute

Nashville, Tennessee, United States

St. David's South Austin Medical Center

Austin, Texas, United States

MD Anderson Cancer Center

Houston, Texas, United States

Texas Transplant Institute

San Antonio, Texas, United States

Swedish Cancer Institute

Seattle, Washington, United States

St Vincents Hospital Melbourne

Fitzroy, Australia

The Alfred Hospital

Melbourne, Australia

Fiona Stanley Hospital

Murdoch, Australia

Calvary Mater Newcastle Hospital

Waratah, Australia

Princess Margaret Cancer Centre University Health Network

Toronto, Ontario, Canada

Rigshospitalet

Copenhagen, Denmark

Odense University Hospital

Odense, Denmark

Erasmus MC

Rotterdam, Netherlands

UMC Utrecht

Utrecht, Netherlands

Seoul National University Hospital

Seoul, South Korea

Asan Medical Center

Seoul, South Korea

Samsung Medical Center

Seoul, South Korea

Hosp Univ Vall D Hebron

Barcelona, Spain

Hosp Clinic de Barcelona

Barcelona, Spain

ICO L'Hospitalet - Hospital Duran i Reynals

Barcelona, Spain

Hosp Univ Fund Jimenez Diaz

Madrid, Spain

University College London Hospitals

London, United Kingdom

The Christie NHS Foundation Trust Christie Hospital

Manchester, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05421663

Related Trials

Tissue Collection for Studies of Lymph Cancer

NCT016768052 locations

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

NCT026826671 location

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

NCT06890884119 locations

A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

NCT0546326315 locations

AI-based Predictive and Interventional System for Early Detection of Non-compliance Risks With Oral Therapies in Lymphoma Patients.

NCT075461881 location